These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25604780)

  • 21. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience.
    Sperlongano S; Gragnano F; Natale F; D'Erasmo L; Concilio C; Cesaro A; Golia E; Crisci M; Sperlongano R; Fimiani F; Russo M; Arca M; Limongelli G; Calabrò P
    J Cardiovasc Med (Hagerstown); 2018 Mar; 19(3):83-90. PubMed ID: 29389816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia.
    Kolovou GD; Kolovou V; Papadopoulou A; Watts GF
    J Atheroscler Thromb; 2016 Jul; 23(7):878-83. PubMed ID: 27170061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
    Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
    J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.
    Davis KA; Miyares MA
    Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JCL roundtable: drug treatment of severe forms of familial hypercholesterolemia.
    Brown WV; Rader DJ; Goldberg AC
    J Clin Lipidol; 2014; 8(1):10-7. PubMed ID: 24528683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.
    Roeters van Lennep J; Averna M; Alonso R
    J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial hypercholesterolemia: etiology, diagnosis and new treatment options.
    Gouni-Berthold I; Berthold HK
    Curr Pharm Des; 2014; 20(40):6220-9. PubMed ID: 24953396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigational therapies for the treatment of atherosclerosis.
    Tomkin GH; Owens D
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1411-21. PubMed ID: 24857672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Severe familial hypercholesterolemia treatment].
    Vrablík M; Freiberger T; Bláha V; Češka R
    Vnitr Lek; 2016; 62(11):895-901. PubMed ID: 28128576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging low-density lipoprotein therapies: Microsomal triglyceride transfer protein inhibitors.
    Goldberg AC
    J Clin Lipidol; 2013; 7(3 Suppl):S16-20. PubMed ID: 23642324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial hypercholesterolemia.
    Bouhairie VE; Goldberg AC
    Cardiol Clin; 2015 May; 33(2):169-79. PubMed ID: 25939291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of microsomal triglyceride transfer protein inhibitors in the treatment of patients with familial hypercholesterolemia: risks, benefits, and management.
    Ahmad Z; Khera A
    Curr Atheroscler Rep; 2015 Jan; 17(1):469. PubMed ID: 25408543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Homozygous familial hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B].
    Alonso R; Mata P; Alonso Y Gregorio M; de Andrés R
    Med Clin (Barc); 2015 Sep; 145(5):229-30. PubMed ID: 25543225
    [No Abstract]   [Full Text] [Related]  

  • 34. Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child.
    Chacra APM; Ferrari MC; Rocha VZ; Santos RD
    J Clin Lipidol; 2019; 13(3):397-401. PubMed ID: 30948303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review.
    Neef D; Berthold HK; Gouni-Berthold I
    Expert Rev Clin Pharmacol; 2016; 9(5):655-63. PubMed ID: 26943823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel pharmacotherapies of familial hyperlipidemia.
    Drakopoulou M; Toutouzas K; Stefanadis C
    Pharmacol Ther; 2013 Sep; 139(3):301-12. PubMed ID: 23639874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Endo M; Kusakabe N; Tanioka T; Kato H; Shoji T
    Atherosclerosis; 2006 May; 186(1):126-31. PubMed ID: 16043185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.